Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.2376 | 0.2376 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.002 | 0 | 0.5 |
Onchocerca volvulus | 0.0054 | 0.8528 | 0.8528 | |
Leishmania major | hypothetical protein, conserved | 0.002 | 0 | 0.5 |
Onchocerca volvulus | 0.0054 | 0.8528 | 0.8528 | |
Brugia malayi | Low-density lipoprotein receptor repeat class B containing protein | 0.0025 | 0.1249 | 0.1249 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.1249 | 0.1249 |
Onchocerca volvulus | 0.0054 | 0.8528 | 0.8528 | |
Onchocerca volvulus | 0.006 | 1 | 1 | |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.002 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0054 | 0.8528 | 0.8528 |
Schistosoma mansoni | hypothetical protein | 0.0054 | 0.8528 | 1 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.002 | 0 | 0.5 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0026 | 0.1535 | 0.18 |
Toxoplasma gondii | kringle domain-containing protein | 0.002 | 0 | 0.5 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.002 | 0 | 0.5 |
Onchocerca volvulus | Arrow homolog | 0.0025 | 0.1249 | 0.1249 |
Loa Loa (eye worm) | low-density lipoprotein receptor repeat class B containing protein | 0.0025 | 0.1249 | 0.1249 |
Echinococcus granulosus | tissue type plasminogen activator | 0.002 | 0 | 0.5 |
Brugia malayi | SEA domain containing protein | 0.0054 | 0.8528 | 0.8528 |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.0054 | 0.8528 | 0.8528 |
Onchocerca volvulus | 0.0054 | 0.8528 | 0.8528 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 25 uM | Cytotoxicity against human HCT116 cells after 120 hrs by hemocytometer | ChEMBL. | 24588245 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.